Combination immune checkpoint therapy carried on despite grade 4 immune-related hepatotoxicity during treatment of metastatic melanoma: Case report and review of literature

• Published in: Clinics and research in hepatology and gastroenterology Vol. 47; no. 8; p. 102192
• Main Authors: Lallement, Angèle, Lamoureux, Anouck, Hummelsberger, Michael, Maria, Alexandre, Meunier, Lucy
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.10.2023; Elsevier
• Subjects: Cancer; Dermatology; Hepatitis; Human health and pathology; Hépatology and Gastroenterology; Immune checkpoint inhibitors; Immune-related adverse events; Life Sciences; Melanoma; ASCO; AST; Immune-related adverse events; PT; ALP; Melanoma; ALT; Immune checkpoint inhibitors; UDCA; CTC-AE; ICI; ESMO; Hepatitis; GGT; irAE; irH; Cancer; cancer; hepatitis; immune-related adverse events
• ISSN: 2210-7401; 2210-741X; 2210-741X
• DOI: 10.1016/j.clinre.2023.102192

We report the case of a 63-year-old patient with recurrence of acral malignant melanoma after adjuvant immune checkpoint inhibitors (ICI) treatment by PEMBROLIZUMAB complicated with immune-related grade II hepatitis. Rechallenge by combination immune checkpoint (NIVOLUMAB + IPILIMUMAB) led to a relapse of the immune-related hepatitis up to a grade 3. Combination ICI therapy was carried on after introduction of corticosteroid therapy. Here, we present the outcomes of this immune-related adverse event (irAE) and a review of literature on the subject.